Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR 238.75
-3.45 (-1.42%)
At close: Jul 27, 2026
Medicamen Biotech Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 2,009 | 2,009 | 1,675 | 1,793 | 1,409 | 1,154 |
Revenue Growth | 19.90% | 19.90% | -6.56% | 27.29% | 22.02% | 2.42% |
Gross Profit Gross Profit Growth | 991.11 | 991.11 | 810.61 | 852.01 | 674.19 | 612.38 |
Operating Income Operating Income Growth | 154.82 | 154.82 | 117.92 | 152.57 | 176.32 | 178.96 |
Net Income Net Income Growth | 96.41 | 96.41 | 71.08 | 109.31 | 148.44 | 148.98 |
Earnings Per Share EPS Growth | 7.11 | 7.11 | 5.59 | 8.63 | 11.73 | 12.19 |
EPS Growth | 27.15% | 27.15% | -35.25% | -26.41% | -3.78% | 22.82% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 312.64 | 312.64 | 37.59 | 147.86 | 207.79 | 38.25 |
Total Debt Total Debt Growth | 477.84 | 477.84 | 337.74 | 311.12 | 257.09 | 257.96 |
Net Cash (Debt) Net Cash Growth | -165.19 | -165.19 | -300.15 | -163.26 | -49.3 | -219.71 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -12.18 | -12.18 | -23.61 | -12.90 | -3.90 | -17.98 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -331.72 | -331.72 | -81.59 | -67.44 | -62.93 | 41.09 |
Capital Expenditures CapEx Growth | -47.78 | -47.78 | -21.89 | -62.87 | -66.01 | -86.08 |
Free Cash Flow Free Cash Flow Growth | -379.5 | -379.5 | -103.47 | -130.31 | -128.94 | -44.99 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 49.34% | 49.34% | 48.38% | 47.52% | 47.86% | 53.04% |
Operating Margin | 7.71% | 7.71% | 7.04% | 8.51% | 12.52% | 15.50% |
Pretax Margin | 5.97% | 5.97% | 5.90% | 7.29% | 12.10% | 15.67% |
Profit Margin | 4.80% | 4.80% | 4.24% | 6.10% | 10.54% | 12.90% |
FCF Margin | -18.89% | -18.89% | -6.18% | -7.27% | -9.15% | -3.90% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
Dividend Per Share Growth | 0% | 0% | 0% | 0% | 0% | 0% |
Dividend Yield | 0.42% | 0.45% | 0.21% | 0.26% | 0.15% | 0.16% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 33.59 | 29.63 | 86.16 | 44.56 | 55.87 | 52.79 |
PS Ratio | 1.51 | 1.42 | 3.66 | 2.72 | 5.89 | 6.81 |